This 'investment by TDM was signaled in the last 2 AGMs, even the amount 75 mill or thereabouts. Guess TDM hedged and finally pulled trigger when Stelfonta got FDA approval. However the number of CRs including this one for wound healing is getting tiring. Odd that they are citing marketing of Stelfonta as a reason. Isnt that Virbacs job, esp as they are getting 50% of proceeds?More wary of management for sure, esp with you know who on board now. Wonder how much more dilution is in store with listing possibly around the corner.
Another thing, prospectus being produced in part cos investors want more clarity about where this investment is going and the road ahead. Instead of just a few words about wound healing, marketing of Stelfonta, blah blah.
As for revenue, Qbiotics not bragging about it for sure. However quite a bit of very positive commentary on social media. This one on Facebook is pretty noteworthy. For a subcutaneous MCT above the hock, specifically ear. Supposedly not approved, but owner eventually found a vet that would proceed with Stelfonta. Another amazing outcome.
